Peptidoglycan-associated lipoprotein (PAL) is a ubiquitous gram-negative bacterial outer-membrane protein that is shed by bacteria into the circulation of septic animals. We explored the inflammatory effects of purified PAL and of a naturally occurring form of PAL that is shed into serum. PAL is released into human serum by Escherichia coli bacteria in a form that induces cytokine production by macrophages and is tightly associated with lipopolysaccharide (LPS). PAL activates inflammation through TLR2. PAL and LPS synergistically activate macrophages. These data suggest that PAL may play an important role in the pathogenesis of sepsis and imply that physiologically relevant PAL and LPS are shed into serum and act in concert to initiate inflammation in sepsis.
patterns of activation and signaling pathways between various TLR agonists, which suggests that interplay between TLRs may be important in defining inflammatory responses in sepsis [10, [21] [22] [23] [24] .
To eliminate confounding effects of contaminants, investigators have used chemically prepared or synthesized compounds to study TLR-mediated responses. However, it seems likely that the composition of microbial components that are released into the circulation in sepsis differs substantially from these highly pure agonists.
LPS is a critical bacterial mediator of sepsis [25, 26] . Bacterial peptidoglycan-associated lipoprotein (PAL) is an outer-membrane protein (OMP) that is highly conserved among different genera of enteric gram-negative bacteria [27] [28] [29] . PAL is involved in maintaining cellwall integrity and is structurally similar to other microbial lipoproteins [29] [30] [31] [32] . PAL is composed of 152 amino-acid residues and glyceride and acyl groups that are attached to the N-terminal cysteine [27, 28, 32] . We previously reported that Escherichia coli bacteria release complexes of LPS and several OMPs-including PAL, Figure 1 . Peptidoglycan-associated lipoprotein (PAL) shed into human serum in a form that activates macrophages. Escherichia coli bacteria were incubated in normal human serum for 4 h; then, the serum was filtered to remove bacteria. The resultant bacteria serum filtrate (BSF) was incubated overnight at 4؇C with anti-PAL and control immunoglobulin beads, and the beads were washed with PBS. A, Immunoblots: detection of PAL by immunoblotting using 5 mL beads/well. Rabbit anti-PAL IgG was used as the primary antibody. A representative immunoblot of a sample prepared using E. coli O18 bacteria is shown. PAL was detected in anti-PAL/BSF samples (left lane) but not in control immunoglobulin/BSF samples (middle lane). Right lane, Purified PAL. B, Macrophage assay using anti-PAL/BSF and control immunoglobulin/BSF samples, prepared by use of E. coli O18 bacteria. Samples were suspended in and diluted further with medium (300 mL/10 mL of beads, followed by serial 5-fold dilutions) and then incubated overnight with bone marrow-derived macrophages (BMDMs) from C3H/HeJ and C3H/HeN mice. Interleukin (IL)-6 levels were measured in supernatants. The PAL content of the anti-PAL/BSF beads was 22 ng/mL beads. The total volume in the wells (beads plus medium) was 125 mL. The wells contained 0.16, 0.8, or 4 mL beads/well (28, 140 , and 700 ng/mL of PAL, respectively). d, IL-6 was not detectable. * , Bonferroni's multiple comparison P ! .001 test, anti-PAL/BSF vs. control immunoglobulin/BSF. C, Macrophage assay that used anti-PAL/BSF and control immunoglobulin/BSF samples that were prepared by use of wild-type (wt) and PAL-deletion bacteria. Samples were suspended in medium (300 mL medium/10 mL beads) and then incubated overnight with BMDMs from C3H/HeJ and C3H/HeN mice as described above. IL-6 levels were measured in supernatants. d, IL-6 not detectable. * , Bonferroni's multiple comparison test, anti-PAL/BSF prepared with wt vs. PAL-deletion bacteria. wells/condition. Immunoglobulin-P ! .001 n p 3 conjugated beads were free of lipopolysaccharide, according to the Limulus-amebocyte lysate assay, and did not activate macrophages. IL-6 was not induced in macrophages treated with control samples that were prepared from filtered human serum that was not incubated with bacteria. replicates/condition. n p 3-4 murine lipoprotein (MLP), and OmpA-into the blood of septic rats [33] [34] [35] . We also found that PAL is shed into the circulation in a peritonitis model, that purified PAL induces inflammation in LPS-hyporesponsive (C3H/HeJ) mice, and that E. coli bacteria that express abnormal PAL are less virulent than their wild-type (wt) progenitors in a peritonitis sepsis model [36] . In the present study, we explored the inflammatory effects of a "physiological" form of PAL that is shed into serum by bacteria, confirmed that PAL activity is TLR2-specific in vitro and in vivo, and tested the hypothesis that PAL and LPS are synergistic.
MATERIALS AND METHODS
Bacteria. E. coli O18:K1:H7 (E. coli O18) was a gift from A. Cross (University of Maryland, Baltimore). E. coli K12 CH202(pRC2) was a gift from U. Henning (Max-Planck-Institut, Tübingen, Germany) [28] . Other E. coli K12 strains were prepared by J.-C.L. and included JC1129 (PAL wt), JC2721 (1129 pal892 [nonsense mutation resulting in PAL-null phenotype] nadA::Tn10), JC8056 (PAL wt), and JC7752 (PAL/TolB deletion derivative of JC8056) transformed with PJC2514, a plasmid that expresses TolB (which renders the strain a functional PAL deletion) [30, 37, 38] LPS. E. coli J5 LPS was purchased (List Biological Laboratories) and was determined to be free of protein by use of gold stains and immunoblots for OmpA, PAL, and MLP [39] .
Cell lines. Cell lines were incubated at 37ЊC in humidified 5% CO 2 . Human embryonic kidney (HEK) 293 cells were a gift from D. Golenbock (University of Massachusetts, Worcester). RAW 264.7 cells were purchased (American Type Culture Collection). HEK-293 and RAW 264.7 cells were maintained in Dulbecco's modified Eagle medium (DMEM) with 10% fetal calf serum and penicillin/streptomycin (PCN/Strep).
Plasmids. Human TLR2 and TLR4 expression plasmids were a gift from C. Kirschning and M. Rothe (Tularik, South San Francisco, CA) [40] . A plasmid expressing b-galactosidase (bgal) via the constitutively active heat-shock protein promoter (hsp-lacZ) was used as an internal standard. A wt E-selectin promoter reporter (ELAM-luciferase) has been described elsewhere [41] . A plasmid encoding a dominant-negative form of MyD88 (DN MyD88) was a gift from D. Golenbock [42] .
Mice. The Institutional Animal Care and Use Committee at Massachusetts General Hospital (MGH) and Boston Medical Center approved the animal studies. The mice used were C3H/ HeJ and C3H/HeOuJ (Jackson Laboratories), C3H/HeN and C57BL/6 (Charles River Laboratories), and TLR2 knockout (KO) mice. C3H/HeJ mice contain a mutation in the TLR4 gene that makes them hyporesponsive to LPS [3] . TLR2 KO mice were generated and bred onto the C57BL/6 background strain by S. Akira (Osaka University, Osaka, Japan) [7] .
Antibodies. Mouse monoclonal anti-PAL IgG and rabbit polyclonal anti-PAL IgG were prepared as described elsewhere [33, 34, 36] . Anti-PAL IgGs do not bind to serum components or to other bacterial products by immunoblotting. PAL purification. PAL was prepared from E. coli K12 CH202(pRC2), as described elsewhere [36] ; it contained a single protein, as assessed by gold staining. All PAL preparations contained !5 pg LPS/1 mg protein, according to the Limulusamebocyte lysate (LAL) assay (Associates of Cape Cod) [43] .
Preparation of mouse macrophages. Thioglycollate-elicited peritoneal macrophages (PMs) were prepared and plated as described elsewhere [36, 44] . Bone marrow-derived macrophages (BMDMs) were prepared as described elsewhere [45] . Briefly, stem cells were harvested from the femurs of 1-2 mice and placed in -cm Teflon bags (BioFOLIE; Sartorius) that 5 ϫ 30 were prepared with the hydrophobic side facing inward. BMDMs replicates/condition. n p 3 were incubated for 7 days and were harvested, plated (at cells/cm 2 ), and allowed to adhere for 24-48 h. 5 4 ϫ 10 Preparation of IgG-conjugated sepharose beads for capture experiments. Cyanogen bromide-activated sepharose 4B beads (Amersham Pharmacia Biotech) were coupled with mouse anti-PAL IgG and control mouse IgG. The IgG-conjugated beads were blocked overnight (in 5% milk at 4ЊC) and then were washed with PBS. Beads were then suspended in PBS that contained 1.8 mol/L NaCl and 0.1% Tween-20 (10 mL beads/400 mL PBS).
Capture of serum-released PAL. E. coli O18 and wt and PAL-deletion E. coli K12 bacteria were cultured to OD 550 0.8 ( bacteria/mL) and washed in sterile saline. The bacterial 8 4 ϫ 10 pellets were suspended in an equal volume of normal human serum and incubated (for 4 h at 37ЊC). The serum was then centrifuged at 6000 g and passed through a 0.45-mm filter to remove bacteria. The resultant bacterial serum filtrate (BSF) was added to anti-PAL and control immunoglobulin beads (100 mL BSF/400 mL washed and resuspended beads). Samples were incubated overnight at 4ЊC with end-over-end rotation. Unbound material was separated from the beads by centrifugation (at 250 g for 5 min), and the beads were washed with PBS. The final samples (hereafter called "anti-PAL/BSF" and "control immunoglobulin/BSF") were used in macrophage assays and were analyzed for PAL by immunoblots and for LPS by use of the LAL assay. Control samples were prepared from serum that was treated in a fashion identical to that described above but without bacteria.
Immunoblots. Immunoblots were used to detect PAL in anti-PAL/BSF and control immunoglobulin/BSF samples, as described elsewhere [33, 46] . Densitometry was performed to quantify PAL in lanes of the immunoblots by use of a ChemiImager 5500 imaging system (Alpha Innotech) and a standard curve of purified PAL.
Macrophage assays using anti-PAL/BSF and control immunoglobulin/BSF samples. Anti-PAL/BSF and control immunoglobulin/BSF samples were suspended in medium and incubated overnight with C3H/HeN or C3H/HeJ BMDMs. Interleukin (IL)-6 levels were measured in culture supernatants by ELISA (R&D Systems). Purified LPS was used as a control to verify LPS unresponsiveness of the C3H/HeJ macrophages. replicates/condition. n p 3 IL-6 responses to chemically purified PAL were comparable in BMDMs from C3H/HeJ and C3H/HeN mice.
Human whole-blood and peripheral-blood macrophage assays. The institutional review board at MGH approved these studies. Citrated whole blood was collected by venipuncture from healthy human volunteers. Whole blood was diluted 4-fold with RPMI 1640 medium and l-glutamine (Cellgro; Mediatech) and then incubated for 20 h with purified PAL. The cells were removed by centrifugation (at 1000 g for 5 min), and IL-6 in the supernatants was quantified by ELISA. Monocytes and macrophages were purified from peripheral blood mononuclear cells (PBMCs) that were prepared from citrated whole blood as described elsewhere [44] . PBMCs were washed with PBS, suspended in PBS with 2 mmol/L EDTA and 10% autologous plasma, and passed through a filter to remove clumps. Macrophages were prepared by magnetic depletion of other cells by use of an anti-lineage antibody mixture and passage through a magnetic column, according to the manufacturer's instructions (VarioMacs; Miltenyi Biotec). Cells in the flow-through were washed and suspended in medium (DMEM with glutamine, 10% autologous plasma, and PCN/ Strep) and were plated ( cells/cm 2 ) and allowed to ad-5 5 ϫ 10 here for 1-2 h. Monocytes and macrophages were incubated for 20 h with PAL, and IL-6 levels were measured in culture supernatants by ELISA.
Stimulation of mouse macrophages with PAL and LPS. Studies were performed with use of macrophages from C3H/ HeJ, C3H/HeN, C3H/HeOuJ, C57BL/6, and TLR2 KO mice and RAW 264.7 cells. Macrophages were treated with PAL and/ or LPS for 20 h, and cytokine levels were measured in the culture supernatants by ELISA. Nitrite production was quantified in the absence and presence of interferon (IFN)-g (10 U/mL) by use of the Greiss reaction [44] . Components were added to the wells in the following order: medium, LPS, and PAL. In some experiments, polymyxin B (PmxB; 5 mg/mL) was also added to wells.
Preparation of heat-killed bacteria. wt and PAL-mutant E. coli K12 strains were cultured to OD 550 0.8 and were washed and resuspended in sterile saline. Quantitative cultures were performed on tryptic soy agar plates. Bacteria were killed by incubation at 100ЊC for 40 min. Heat-killed bacteria were diluted in medium to the concentration required to achieve an MOI of 5 bacteria/HEK-293 cell. Quantitative cultures were performed to verify that the heat-treated bacteria were dead.
Transient transfections. Transfections were performed when HEK-293 cells reached 70%-80% confluence by use of FuGENE 6 Transfection Reagent (Roche Diagnostics). A total of 2 mg of plasmid DNA was suspended in 100 mL of OptiMEM reduced serum medium (Life Technologies). Each condition included 100 ng of ELAM-luciferase reporter plasmid and 50 ng of hsplacZ as an internal standard. Additional human constructs added to different wells included (1) TLR2 (10 ng), (2) TLR2 (10 ng) and DN MyD88 (100 ng), and (3) TLR4 (10 ng). A constant amount of plasmid DNA was maintained by the inclusion of the empty vector pcDNA3.1. Transfected cells were treated for 6 h with PAL, LPS, or heat-killed bacteria, and cells were harvested. Luciferase activity was measured on 20-mL cell lysates by use of the Luciferase Assay System (Promega). b-gal activity was also measured from each transfection condition. Equal volumes of cell lysate and 2-fold concentrated b-gal assay buffer (200 mmol/L sodium phosphate, dibasic dehydrate [pH 7.3], 2 mmol/L MgCl 2 , 100 mmol/L 2-mercaptoethanol, and 1.33 mg/mL j-nitrophenyl-b-d-galactopyranoside) were incubated together (for 30 min at 37ЊC), and the optical density (not shown). Splenocytes were incubated with PAL (1 mg/mL) for 40 h and were then pulsed with 3 H-thymidine (1 mCi/well) for an additional 18 h. Liquid scintillation counting was used to assess the uptake of 3 H into proliferating cells (C). Lipopolysaccharide (LPS) was used as a positive control to demonstrate that TLR2-deficient cells were capable of responding normally when they were stimulated via TLR4. The LPS concentrations were 100 ng/mL and 1 mg/mL, respectively, for macrophage and splenocyte assays. In vivo responses were also studied in wt and TLR2 KO mice in 2 experiments (D). Mice received an intravenous (iv) injection of PAL (25 mg), and IL-6 levels were quantified in their plasma 90 min later. The results were identical for TNF-a and MIP-1a. LPS (100 ng iv) was used as a positive control to verify that the TLR2 KO mice could respond to a TLR4 agonist. mice/group. For all graphs, left n p 3 and middle bars, PAL; right bar, LPS. CPM, counts per minute. Figure 6 . Activation of Toll-like receptor 2 (TLR2)-transfected HEK-293 cells by heat-killed wild-type (wt) and peptidoglycan-associated lipoprotein (PAL)-mutant Escherichia coli K12 bacteria. HEK-293 cells were transiently transfected with plasmid constructs for ELAM-Luc and hsplacZ plus TLR2 and then were treated for 6 h with E. coli K12 bacteria that expressed normal PAL (wt, white bars) or with E. coli K12 strains that completely lack PAL (PAL-Del, black bar) or that expressed abnormal PAL because of a nonsense mutation (PAL-Nons, black bar). Luciferase activity was measured and is reported as the corrected luciferase (based on b-galactosidase expression) divided by control luciferase (cells transfected with ELAM-Luciferase and hsp-lacZ). replicates/condition. n p 3 at 420 nm was measured. The luciferase activity of each condition was divided by its corresponding b-gal activity, to accommodate differences in replicate transfection efficiency. The corrected luciferase activity was then divided by the luciferase activity in HEK-293 cells that were transfected by ELAM-luciferase and hsp-lacZ alone.
Splenocyte proliferation. Splenocytes were prepared from C57BL/6 and TLR2 KO mice and used as described elsewhere [36, 44] . Briefly, splenocytes were treated with PAL and then were pulsed with 3 H-thymidine. The incorporation of 3 H-thymidine was assessed by liquid scintillation counting.
Systemic cytokine responses of wt and TLR2 KO mice. Mice received an intravenous injection of purified PAL or LPS. At 90 min, mice were killed, and blood was collected by cardiac puncture. Cytokine levels were quantified in plasma by ELISA.
Statistical analysis. Error bars represent SDs. Responses to purified PAL were analyzed by 1-way ANOVA, followed by Dunnett's multiple comparisons post-hoc test to determine threshold activating concentrations of PAL. Bonferroni's multiple comparison test was used to compare responses of PALtreated C3H/HeOuJ macrophages in the presence and absence of PmxB, wt and TLR2 KO cellular and systemic responses, transfected HEK-293 cell responses to PAL and heat-killed bacteria, and macrophage responses to anti-PAL/BSF and control immunoglobulin/BSF. Unless otherwise indicated, representative data from at least 3 experiments are presented. was P ! .05 considered to be statistically significant.
RESULTS
Release of biologically active quantities of PAL into human serum by E. coli. Immunoblots were performed to detect PAL in samples that were captured from filtrates of human serum incubated with bacteria (BSF) by use of antibody-coated beads. BSF samples were prepared by use of E. coli O18 and wt and PAL-deletion strains of E. coli K12 bacteria. A representative immunoblot is shown in figure 1A . PAL was detected in anti- replicates/condition. PAL n p 3 preparations used for synergy experiments all contained !1 pg LPS/mg protein, and the LPS was protein-free, as assessed by gold stains and immunoblots for outer-membrane protein A, PAL, and murein lipoprotein.
PAL/BSF samples that were prepared by use of E. coli O18 and wt E. coli K12 but not in anti-PAL/BSF samples that were prepared by use of the PAL-deletion mutant. PAL was also not detected in any samples that were prepared with control immunoglobulin beads. We quantified PAL in the anti-PAL/BSF samples in 2 experiments by densitometry of bands on immunoblots that used a standard curve of purified PAL. PAL quantities were 110 ng/ lane (experiment 1) and 198 ng/lane (experiment 2). Each lane contained 5 mL of beads that represented a starting BSF volume of 50 mL. Thus, the concentration of PAL in the BSF that was captured by anti-PAL beads was 2.2 mg/mL in experiment 1 and 3.96 mg/mL in experiment 2.
LPS copurification with PAL. LPS was quantified in affinity-purified samples by use of the LAL assay. For samples prepared with E. coli O18 bacteria, LPS levels per 10 mL of beads were 93 pg (experiment 1) and 99 pg (experiment 2) for anti-PAL/BSF samples and were 57 pg (experiment 1) and 50 pg (experiment 2) for control immunoglobulin/BSF samples. The anti-PAL and control immunoglobulin beads were free of LPS, according to the LAL assay. Because anti-PAL IgG does not specifically bind LPS, the 1.6-2-fold higher levels of LPS in anti-PAL/BSF samples suggest that serum-released PAL and LPS are tightly associated.
Activation of macrophages by serum-released PAL. Cytokines were quantified in supernatants of BMDMs that were treated with anti-PAL/BSF and control immunoglobulin/BSF. Initial experiments were performed by use of E. coli O18 bacteria. Anti-PAL/BSF induced IL-6 production by both C3H/ HeJ and C3H/HeN macrophages, whereas IL-6 was not significantly induced in macrophages treated with control immunoglobulin/BSF ( ) ( figure 1B) .
We performed additional experiments to verify that PAL is responsible for the inflammatory effects of the anti-PAL/BSF samples. Macrophages were treated with anti-PAL/BSF and control immunoglobulin/BSF samples that were prepared by use of wt and PAL-deletion bacteria. Cytokine production was reduced (C3H/HeN) or eliminated (C3H/HeJ) in anti-PAL/BSF samples that were prepared with the PAL deletion, compared with the wt bacteria ( ) ( figure 1C , shown for IL-6). P ! .001 Induction of cytokine production in human cells by PAL. PAL was incubated with whole blood and adherent peripheral blood monocytes and macrophages from 4 and 5 donors, respectively. PAL caused an increase in IL-6 production by whole blood ( ) ( figure 2A ) and by peripheral blood-adherent P ! .0001 monocytes and macrophages ( ) ( figure 2B ). There was P ! .0001 considerable variability between responses of cells from different donors. Whole-blood responses were statistically significant for all donors at PAL concentrations у400 ng/mL. Monocyte and macrophage responses were significant for all donors at PAL concentrations у10 ng/mL. Activation of mouse macrophages by purified PAL. To extend our prior studies that indicated that PAL activates PMs from LPS-hyporesponsive mice, we studied responses of macrophages from LPS-responsive mice and from different macrophage compartments. PAL increased cytokine production by BMDMs and PMs from all strains of mice tested at threshold PAL concentrations of 1-100 ng/mL, depending on the cell lineage and the cytokine ( ) (figure 3A-C). PmxB did P ! .0001 not inhibit the effects of PAL on IL-6 production by C3H/ HeOuJ macrophages, which supports the LAL data that our purified PAL did not contain biologically relevant quantities of LPS ( ; data not shown). PAL also activated production P 1 .05 of nitrite by PMs and BMDMs at threshold PAL concentrations of 1-10 ng/mL ( ) ( figure 3D ). IFN-g was not required P ! .001 for the PAL-induced production of nitrite by C57BL/6 PM ( ), but it was required for the PAL-induced production P ! .0001 of nitrite by C57BL/6 BMDMs and C3H/HeN PMs ( figure 3D ). The source of the difference in this requirement of IFN-g between the cell types is not clear. Other investigators have also reported heterogeneity in responses of leukocytes from different compartments [47] . It is possible that signaling pathways vary between cells in different compartments or that the PMs were primed by the thioglycollate that was used to elicit the PMs. PAL caused an increase in tumor necrosis factor (TNF)-a, IL-6, and nitrite production by the macrophage-like cell line RAW 264.7 at threshold concentrations of 1-10 ng/mL ( ; data P ! .01 not shown). We have previously reported that PAL is released into the blood of mice in a cecal ligation and puncture (CLP) sepsis model and estimated that PAL levels were у130 ng/mL in some CLP mice [36] , which is considerably higher than the threshold activating concentrations of PAL in the present study.
TLR2-and MyD88-mediated inflammatory effects of PAL. HEK-293 cells were transiently transfected with reporter plasmids (ELAM-luciferase and hsp-lacZ) plus expression plasmids encoding human TLR2, human TLR2 plus DN MyD88, or human TLR4, and then were treated with PAL or LPS. MyD88 is an intracellular adapter molecule that is required for signaling by some TLRs. The DN MyD88 construct was used to confirm that PAL activation is fully dependent on TLRs. PAL activated ELAMluciferase in TLR2-transfected cells but not in cells transfected with only the reporter construct or with the TLR4 construct ( ) (figure 4). The DN MyD88 construct fully inhibited P ! .001 activation of TLR2-transfected cells by PAL ( ). P ! .001 Mediation of PAL-induced inflammation by TLR2 in mice. We compared responses of BMDMs and splenocytes from C57BL/6 and TLR2 KO mice. PAL induced IL-6, TNF-a, macrophage inflammatory protein (MIP)-1a, and nitrite production by macrophages from wt mice but not by macrophages from TLR2 KO mice ( ) ( figure 5A -B, shown for IL-6 P ! .001 only). PAL also increased the proliferation of splenocytes from wt but not from TLR2 KO mice ( ) (figure 5C). Plasma P ! .001 TNF-a, IL-6, and MIP-1a levels were measured in PAL-treated mice. PAL activated systemic cytokine responses in wt but not in TLR2 KO mice ( ) ( figure 5D , shown for IL-6 and P ! .001 nitrite only).
Effects of wt versus PAL-mutant bacteria on TLR2-transfected cells. To determine whether PAL contributes to the TLR2-mediated activation of whole bacteria, TLR2-transfected HEK-293 cells were incubated with heat-killed strains of wt E. coli K12 bacteria and derivatives that contained PAL-nonsense or PAL-deletion mutations. There was no reduction in luciferase activation in TLR2-transfected cells in the PAL-mutant strains, compared with the wt strain (figure 6).
Synergistic activation of macrophages by PAL and LPS.
Studies were performed by use of PMs (C3H/HeN and C57BL/ 6), BMDMs (C57BL/6), and RAW 264.7 cells. There was marked synergy between PAL and low levels of LPS in inducing cytokine and nitrite production for all cell lineages tested (figure 7, shown for C57BL/6 PMs and BMDMs only). There was variability in the doses of PAL and LPS required for synergy between different cell types and readouts. Synergy was most evident at LPS and PAL concentrations that were near the threshold of activity for the individual component.
DISCUSSION
The present study shows that PAL is a naturally occurring ubiquitous TLR2 agonist that is shed into serum in a biologically active form. We also found that released PAL is tightly associated with LPS and that PAL and LPS are markedly synergistic, which supports the notion that multiple microbial components circulate and modulate the effects of one another in sepsis.
Our studies provide insight into the composition and biological activity of naturally occurring bacterial products that circulate in sepsis. Previous studies of TLR-mediated processes have used synthesized or chemically purified microbial products. We believe that the shed form of PAL that we used is closer in structure and additional content to forms that circulate and contribute to the pathogenesis of human sepsis. The higher IL-6 responses of C3H/HeN versus C3H/HeJ macrophages to anti-PAL/BSF suggest that the PAL and LPS in these naturally occurring products are synergistic. Specific TLR agonists have been shown to modulate inflammatory effects of other TLR agonists. However, the ability of different microbial TLR agonists to influence the inflammatory effects of one another varies markedly between different studies and for different readouts. For instance, consistent with our data, results of other studies have shown synergy between other TLR2 agonists and LPS if they are administered concurrently [48] [49] [50] . There are also reports of cross-tolerance between LPS and TLR2 agonists and between LPS and the TLR9 agonist bacterial DNA [48, [51] [52] [53] . Finally, another study showed that the pretreatment of macrophages with LPS inhibited TNF release and augmented IL-1 release in response to zymosan, a TLR2 agonist, whereas zymosan pretreatment augmented release of both TNF and IL-1 in response to LPS [54] . Thus, it appears that the mechanism(s) by which different microbial products influence responses to one another is highly complex. Further studies will be required to define the pathways that are involved in PAL-LPS synergy.
Over the past several decades, thousands of studies have used various LPS preparations to gain insight into the processes that occur in sepsis. Investigators have noted that LPS preparations often contain proinflammatory protein contaminants [55] [56] [57] .
PAL frequently contaminates purified rough and smooth LPSs [39] , a finding that, together with the present results, raises the possibility that PAL may have contributed to responses in some of these studies aimed at LPS.
In an earlier study [36] , we found that E. coli K12 bacteria expressing abnormal PAL because of a nonsense mutation were less virulent than were their wt progenitors in a peritonitis model. The lack of reduced activity of the heat-killed PAL-mutant versus wt bacteria on TLR2-transfected HEK-293 cells in the present study is likely explained by the presence of other gram-negative bacterial TLR2 agonists, such as OmpA and MLP [14, 58] , and suggests that the reduced virulence observed in our earlier study was not due to decreased PAL in whole bacteria but may have been due to an altered release of PAL. Our data showing that biologically active PAL is shed into serum in tight association with LPS and that PAL and LPS are synergistic suggest that circulating released PAL directly induces inflammation alone and/ or synergistically with other bacterial products.
We hypothesize that, during human sepsis, microorganisms shed fragments that contain multiple PAMPs that activate different pathways and modulate inflammatory responses. Our data suggest that PAL and LPS are part of these released fragments. These results imply that, during sepsis, even very low levels of microbial toxins that are hardly capable of eliciting immune cell responses on their own may contribute significantly to inflammation, through synergy with other microbial components.
